Comments on: Prostate cancer news reports: Saturday, September 12, 2009

By: Sitemaster

Sitemaster — Tue, 15 Sep 2009 01:18:43 +0000

Dear Larm:

If one’s PSA doubling time (PSADT) is, say, 6 months prior to treatment, then any period longer than that (7 months; 11 months; 18 months) would be prolongation. The greater one’s PSA doubling time the better. So a PSADT of 15 months is generally considered to be associated with minimal risk of serious disease progression.

By: Larm

Larm — Mon, 14 Sep 2009 19:43:34 +0000

The study reports a prolongation of PSADT was achieved in 75 percent of patients on study. Can someone please tell us what prolongation of PSADT means in more common terms? I am guessing that this is not bad but if good, how good?

By: Steve Z

Steve Z — Sun, 13 Sep 2009 11:47:18 +0000

“I just report the data!” … Yeah — right ….

By: Sitemaster

Sitemaster — Sat, 12 Sep 2009 21:03:50 +0000

Naproxen is indeed marketed as Aleve, and calcitriol is a formulation of vitamin D3. I just report the data!

By: Steve Z

Steve Z — Sat, 12 Sep 2009 19:10:42 +0000

Am I reading this right?

Aren’t naproxen + calcitriol the same chemicals as Aleve and vitamin D3?